The prescription contains fructus papaveris. According to the limitation for resource of fructus papaveris, SFDA determines that products containing fructus papaveris will not be approved. Thus, it faces smaller and smaller competitiveness.
It is be used to treat cough, dyspnea with rapid and shortbreath, excessive phlegm caused by chronic bronchitis. It is characterized by High treatment efficiency(>91%), low recurrence rate, and no toxic and side effects. It is suitable for broad people.